

Formatted: Tab stops: 15.46 cm, Left

Item 6.2.2a

Quality Committee

Terms of Reference

Formatted: Font: 11 pt

Formatted: Font: 11 pt

For completion by Author			
Author(s) Name and Title:	Sue Pemberton, Director of Nursing and Quality Lucy Lavan, Director of Corporate Affairs		
Scope:	Trust Wide	Classification:	Terms of Reference
Version Number:	6.0	Review Date:	1 st July 2022
Replaces:	Quality Committee Terms of Reference v5.0		
To be read in conjunction with the following documents:	Governance Manual, Provider Licence, Board Assurance Framework		
Document for public display:	Yes		
Executive Lead	Sue Pemberton, Director of Nursing & Quality		

For completion by Approving Committee			
Equality Impact Analysis Completed:	N/A		
Endorsement Completed:	N/A	Record of Changes	N/A
Authorised by:	Board of Directors	Authorisation date:	27 th July 2021

For Corporate Governance Manual documents			
CGM Reference	C4	CGM Review date:	29/07/2022
Authorised by:	Board of Directors	Authorisation date:	27/07/2021

For completion by Document Control					
Unique ID No:	TOR/TB/14(14)	Issue Status:	Approved	Issue Date:	26/08/2021
After this document is withdrawn from use it must be kept in archive for the lifetime of the Trust, plus 6 years.					
Archive:	Document Control		Date Added to Archive:		
Officer responsible for Archive:		Document Control Administrator			

Version No 6.0	Current version is held on the Intranet Check with Intranet that this printed copy is the latest issue	Page 1 of 6
----------------	---	-------------

Contents

1. Constitution and Remit..... 3

2. Authority 3

3. Main Priority and Objective3

4. Duties and Responsibilities3

5. Risk..... 5

6. Equality and Diversity..... 5

7. Integration5

8. Membership.....5

9. Quorum and Frequency6

10. Reporting6

11. Conduct of Committee Meetings6

1. Constitution and Remit

This Committee is established as an Assurance Committee of the Board of Directors of Liverpool Heart and Chest Hospital NHS Foundation Trust in order to provide the Board with assurances in respect of quality governance. It is a Non-Executive Committee

2. Authority

The Quality Committee is authorised by the Board of Directors to investigate any activity within its terms of reference. It is authorised to seek information it requires of any employee (or contractor acting on behalf of the Trust) and all employees (or contractors acting on behalf of the Trust) are directed to co-operate with any request made by the Committee.

The Committee is authorised by the Board to obtain legal advice or other independent professional advice. The Committee is authorised to request the attendance of individuals and authorities from inside or outside of the Trust with relevant experience and expertise, where it considers this is necessary or expedient to the carrying out of its functions.

Trust Standing Orders and Standing Financial Instructions apply to the operation of the Committee.

3. Main Priority and Objective

The Quality Committee shall provide the Board of Directors with a means of independent and Objective review of quality governance. The Committee's main priority is to review and scrutinise assurances that the Trust's strategic priorities for quality and safety improvement are identified,

- i) Ensure that appropriate quality standards in relation to clinical outcomes, safety and patient and family experience are set and compliance with them is monitored;

4. Duties and Responsibilities

The Committee will promote safety and quality in patient care and experience and help to identify priorities and risks arising from clinical care and treatment on a continuing basis.

Specifically the Committee will:

- i) Receive assurances on the content of the Quality Strategy in relation to the targets set and on the quality of data reported to measure these targets
- ii) Assess the clinical and quality impact of financial decisions e.g. Cost Improvement programmes
- iii) Review and scrutinise in-year quality monitoring reports, ensuring the integrity of data
- iv) Seek assurance that the Trust is compliant with external regulations and standards of quality governance, including but not limited to:

- National targets in relation to quality
- Contractual requirements – CQUINs
- Receive the outcome of the EECS assessments from the clinical areas annually

v) **Patient Safety:** Receive assurance that the patient safety agenda is implemented throughout the Trust including:

- Infection prevention and control via the quality report at each meeting and via the Quality Safety Experience Committee (QSEC) key issues report.
- Safeguarding – via the via the key issues report from QSEC
-
- Incident reporting process and implementation of learning from incidents from the IICC report
- Annual report from the medications safety group
- Receive assurances on the management of diabetes across the Trust via the key issues report from QSEC
- Receive monthly updates via the quality dashboard in relation to compliance with the sepsis bundles and improvement works in place and receive updates from the annual report via the QSEC key issues report and report on performance against the trusts sepsis bundle at each meeting

vi) **Clinical Effectiveness:** Receive assurance that the clinical effectiveness agenda is implemented throughout the Trust including via quarterly key issues reports from the QSEC committee meeting and via:

- Updates from any clinical effectiveness initiatives
- Effectiveness of governance processes relating to mortality via an annual mortality assurance paper and via the mortality data presented at each meeting via the quality report and via the key issues report from QSEC
- Receive the clinical audit annual assurance report
- Receipt and review of benchmarking data relating to outcomes
- Assurance around adherence to best practice e.g. NICE guidance, Royal College standards etc
- Receive assurance regarding readmissions and the Trusts improvement plan to reduce incidence [via the QSEC report](#)
- Receive assurance that the trust is meeting the outcomes for cancer services via the key issues report from QSEC
- Receive assurance in relation to compliance with Natsips and Loccsips
- Annually [via the QSEC report](#)
- Receive assurance in relation to resuscitation standards via the key issues report from QSEC
- Receive assurance on the incidence and improvements in preventing falls, and pressure ulcers via the quality report and via the key issues report from QSEC
- Receive assurance on nutritional standards trust wide via the key issues report from the QSEC
- Receive assurance reports regarding progress with the GIRFT Improvement plan [via an annual report](#)
- Receive the root cause analysis for all incidents deemed serious as per the incident reporting policy and assurance that there is a comprehensive action plan in place to address any identified improvements.

Formatted: Font color: Red

Formatted: Font color: Red

- vii) **Patient and Family Experience:** Receive assurance via the quality report that the patient and family experience agenda is implemented throughout the Trust including:
- Receipt of assurance report on action planning in relation to the annual patient survey and the key issues report from QSEC
 - Assurance on quality of data relating to complaints, claims and PALS
 - processes – identification of trends and assurance on implementation of learning via the customer care reports [via the QSEC report](#)
 - Annual assurance report patient and family experience progress via the QSEC
 - key issues report

Formatted: Font color: Red

- viii) **Research & Development:** Receive assurance that the R&D agenda is implemented throughout the Trust including:
- Assurance on data demonstrating implementation of research and innovation strategy via assurance reports

ix) Receive external assurance reports from the CQC and from regulatory / statutory bodies in relation to the quality and patient safety agenda and ensure that management responses / action plans are robust.

x) Consider urgent or material matters referred to the Committee by the Operational Board, Audit Committee or Board of Directors.

5. Risk

The Committee will consider and seek assurances in relation to any risks relating to its remit and will identify and escalate any new or emerging risks arising from its work, through the BAF key issues reporting process. The committee will receive key issues from the risk management committee via the key issues report from QSEC.

6. Equality and Diversity

Ensure that equality and diversity and due consideration to the Human Rights Act are regarded in all aspects of the committee's work. This will include review of any equity analyses that are commissioned against the Trusts clinical services portfolio. In addition the Committee will have regard for NHS constitution in delivering its objectives.

7. Integration

The committee will support the integration of clinical, organisational and financial governance across the Trust.

8. Membership

Three nominated Non-Executive Directors, one of whom will be the Chair and one the Vice Chair. In attendance at all meetings:

Director of Nursing & Quality
Medical Director
[Director of Research & Innovation](#)

Formatted: Font color: Red

All of the above attendees to appoint a nominated Deputy who will attend in his / her absence

Version No 6.0	Current version is held on the Intranet Check with Intranet that this printed copy is the latest issue	Page 5 of 6
----------------	---	-------------

The Committee may invite other officers to attend meetings as required. All Board Members have a right to attend any meeting of the Committee.

9. Quorum and Frequency

In order for decisions taken by the Committee to be valid, the meeting must be quorate. The Chair or Vice Chair plus three other members of the Committee must be present at the point when any business is transacted.

The Committee will meet quarterly (4 times per year).

10. Reporting

The Committee Chair will provide a BAF Key Issues Report to the Board of Directors following each meeting, along with approved minutes and an annual report, which will include a review of the Committee's Terms of Reference.

The Chair of the Committee will escalate urgent matters and exceptions to the Board and / or Audit Committee in between meetings as deemed appropriate.

11. Conduct of Committee Meetings

The Chair of the committee will be supported by a lead Executive Director who will ensure that the appropriate processes are followed:

- Minutes and action log are accurate, comprehensive and timely
- The agenda and supporting papers are sent out to committee members 5 working days prior to the meeting, unless authorised by the Chair for exceptional circumstances
- Authors of papers presented must use the required template and adhere to BAF Policy.
- Presenters of papers can expect all committee members to have read the papers and should keep to a summary that outlines the purpose of their paper/report and key issues.
- Committee members and those in regular attendance should actively participate in discussions pertaining to the agenda, ensuring that solutions and action plans have multidisciplinary perspectives and consideration of Trust-wide impact

